Exicure Inc surges 95.31% on trial success
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Source: 4
Exicure Inc experienced a remarkable pre-market surge of 95.31%, crossing above its 5-day SMA, following the announcement of positive Phase 2 trial results for burixafor.
The trial demonstrated a 90% success rate in mobilizing stem cells for multiple myeloma patients, showcasing the therapy's effectiveness and rapid mobilization advantage. This significant achievement is expected to enhance Exicure's market position and attract further investment.
As the company continues to advance its clinical programs, the positive trial results could lead to increased adoption of burixafor in treating hematologic diseases, potentially expanding Exicure's market opportunities and improving patient outcomes.
Analyst Views on XCUR
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
